Literature DB >> 3927331

Lithium long-term treatment--does it act via serotonin?

B Müller-Oerlinghausen.   

Abstract

The mode of action of lithium salts used in the prophylaxis of affective disorders is still unknown. During the last decade, animal data have provided considerable evidence that chronic administration of lithium within a "therapeutic range" induces 5-HT agonistic effects in the brain. Among other possible reasons this may be due to increased synthesis of 5-HT. After presenting the main animal data in this area, some recent findings in lithium-treated patients are reviewed supporting the biochemical and neurophysiological results. Taking into account that, firstly, lithium possesses antiaggressive effects in animals and men, and secondly, that (auto-)aggression seems to be related to a low concentration of 5-HIAA in CSF, and thirdly, that a close relationship exists between depression and aggressive behavior, the proof of 5-HT agonistic effects in humans may enable us to formulate an integrative theory on the mode of action of lithium salts.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3927331     DOI: 10.1055/s-2007-1017367

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  10 in total

Review 1.  Lithium and serotonin function: implications for the serotonin hypothesis of depression.

Authors:  L H Price; D S Charney; P L Delgado; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Fenfluramine stimulation of serum cortisol in patients with major affective disorders and healthy controls: further evidence for a central serotonergic action of lithium in man.

Authors:  H D Mühlbauer; B Müller-Oerlinghausen
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

3.  Chronic lithium administration enhances serotonin release in the lateral hypothalamus but not in the hippocampus in rats. A microdialysis study.

Authors:  T J Baptista; L Hernández; J L Burguera; M Burguera; B G Hoebel
Journal:  J Neural Transm Gen Sect       Date:  1990

4.  Is Poor Lithium Response in Individuals with Bipolar Disorder Associated with Increased Degradation of Tryptophan along the Kynurenine Pathway? Results of an Exploratory Study.

Authors:  Frederike T Fellendorf; Mirko Manchia; Alessio Squassina; Claudia Pisanu; Stefano Dall'Acqua; Stefania Sut; Sofia Nasini; Donatella Congiu; Eva Z Reininghaus; Mario Garzilli; Beatrice Guiso; Federico Suprani; Pasquale Paribello; Vittoria Pulcinelli; Maria Novella Iaselli; Ilaria Pinna; Giulia Somaini; Laura Arru; Carolina Corrias; Federica Pinna; Bernardo Carpiniello; Stefano Comai
Journal:  J Clin Med       Date:  2022-04-29       Impact factor: 4.964

5.  Lithium-selective permeation through lipid bilayer membranes mediated by a di-imide ionophore with nonsymmetrical imide substituents (ETH1810).

Authors:  A Zeevi; R Margalit
Journal:  J Membr Biol       Date:  1991-04       Impact factor: 1.843

6.  Effects of short-term lithium administration on tryptophan levels and 5-hydroxytryptamine synthesis in whole brain and brain regions in rats.

Authors:  U Berggren
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

7.  Myo-inositol attenuates the enhancement of the serotonin syndrome by lithium.

Authors:  O Kofman; U Levin
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

Review 8.  Response to lithium in bipolar disorder: clinical and genetic findings.

Authors:  Janusz K Rybakowski
Journal:  ACS Chem Neurosci       Date:  2014-03-25       Impact factor: 4.418

9.  Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium.

Authors:  F Artigas; M J Sarrias; E Martínez; E Gelpí; E Alvarez; C Udina
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 10.  Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.

Authors:  Janusz K Rybakowski
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.